These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24778352)

  • 1. MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy.
    Lim TY; Stafford RJ; Kudchadker RJ; Sankaranarayanapillai M; Ibbott G; Rao A; Martirosyan KS; Frank SJ
    Phys Med Biol; 2014 May; 59(10):2505-16. PubMed ID: 24778352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biodistribution and toxicity study of cobalt dichloride-N-acetyl cysteine in an implantable MRI marker for prostate cancer treatment.
    Frank SJ; Johansen MJ; Martirosyan KS; Gagea M; Van Pelt CS; Borne A; Carmazzi Y; Madden T
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1024-30. PubMed ID: 23092727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy.
    Frank SJ; Tailor RC; Kudchadker RJ; Martirosyan KS; Stafford RJ; Elliott AM; Swanson DA; Sing D; Choi J; Mourtada F; Ibbott GS
    Med Dosim; 2011; 36(2):200-5. PubMed ID: 20537886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel MRI marker for prostate brachytherapy.
    Frank SJ; Stafford RJ; Bankson JA; Li C; Swanson DA; Kudchadker RJ; Martirosyan KS
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):5-8. PubMed ID: 18406882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging (MRI) markers for MRI-guided high-dose-rate brachytherapy: novel marker-flange for cervical cancer and marker catheters for prostate cancer.
    Schindel J; Muruganandham M; Pigge FC; Anderson J; Kim Y
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):387-93. PubMed ID: 23433797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment.
    Lim TY; Kudchadker RJ; Wang J; Stafford RJ; MacLellan C; Rao A; Ibbott GS; Frank SJ
    Med Phys; 2016 Jul; 43(7):4312. PubMed ID: 27370146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI of prostate brachytherapy seeds at high field: a study in phantom.
    Thomas SD; Wachowicz K; Fallone BG
    Med Phys; 2009 Nov; 36(11):5228-34. PubMed ID: 19994533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality comparison between three-dimensional T2-weighted SPACE and two-dimensional T2-weighted turbo spin echo magnetic resonance images for the brachytherapy planning evaluation of prostate and periprostatic anatomy.
    Bathala TK; Venkatesan AM; Ma J; Bhosale P; Wei W; Kudchadker RJ; Wang J; Anscher MS; Tang C; Bruno TL; Frank SJ; Szklaruk J
    Brachytherapy; 2020; 19(4):484-490. PubMed ID: 32402544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fiducial marker for prostate radiotherapy: comparison of 0.35- and 0.5-mm-diameter computed tomography and magnetic resonance images.
    Tanaka O; Komeda H; Iida T; Tamaki M; Seike K; Kato D; Hirose S; Kawaguchi D; Yokoyama T
    Radiol Med; 2017 Mar; 122(3):204-207. PubMed ID: 27981486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer.
    De Roover R; Crijns W; Poels K; Peeters R; Draulans C; Haustermans K; Depuydt T
    Med Phys; 2018 May; 45(5):2205-2217. PubMed ID: 29537613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration.
    Parker CC; Damyanovich A; Haycocks T; Haider M; Bayley A; Catton CN
    Radiother Oncol; 2003 Feb; 66(2):217-24. PubMed ID: 12648794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility and value contribution of an MRI-positive line marker for image-guided brachytherapy in gynecologic malignancies.
    Ning MS; Vedam S; Ma J; Stafford RJ; Bruno TL; Cunningham M; Starks C; Lawyer A; Venkatesan AM; Wang L; Wang J; Olivieri ND; Guzman AB; Incalcaterra JR; Thaker NG; Joyner MM; Lin LL; Jhingran A; Eifel PJ; Klopp AH
    Brachytherapy; 2020; 19(3):305-315. PubMed ID: 32265119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-based automated detection of implanted low dose rate (LDR) brachytherapy seeds using quantitative susceptibility mapping (QSM) and unsupervised machine learning (ML).
    Nosrati R; Soliman A; Safigholi H; Hashemi M; Wronski M; Morton G; Pejović-Milić A; Stanisz G; Song WY
    Radiother Oncol; 2018 Dec; 129(3):540-547. PubMed ID: 30243670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registration free automatic identification of gold fiducial markers in MRI target delineation images for prostate radiotherapy.
    Gustafsson C; Korhonen J; Persson E; Gunnlaugsson A; Nyholm T; Olsson LE
    Med Phys; 2017 Nov; 44(11):5563-5574. PubMed ID: 28803447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating platinum coated brachytherapy seeds and gold fiducial markers with varying off-resonant frequency offsets.
    McNabb E; Wong R; Noseworthy MD
    Magn Reson Imaging; 2019 Jul; 60():68-75. PubMed ID: 30959177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience.
    Lim TY; Kudchadker RJ; Wang J; Bathala T; Szklaruk J; Pugh TJ; Mahmood U; Ibbott GS; Frank SJ
    J Contemp Brachytherapy; 2016 Jun; 8(3):235-42. PubMed ID: 27504133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate post-implant dosimetry: interobserver variability in seed localisation, contouring and fusion.
    De Brabandere M; Hoskin P; Haustermans K; Van den Heuvel F; Siebert FA
    Radiother Oncol; 2012 Aug; 104(2):192-8. PubMed ID: 22857857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-alone radiation therapy planning for prostate cancer: Automatic fiducial marker detection.
    Ghose S; Mitra J; Rivest-Hénault D; Fazlollahi A; Stanwell P; Pichler P; Sun J; Fripp J; Greer PB; Dowling JA
    Med Phys; 2016 May; 43(5):2218. PubMed ID: 27147334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose reduction in LDR brachytherapy by implanted prostate gold fiducial markers.
    Landry G; Reniers B; Lutgens L; Murrer L; Afsharpour H; de Haas-Kock D; Visser P; van Gils F; Verhaegen F
    Med Phys; 2012 Mar; 39(3):1410-7. PubMed ID: 22380373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy.
    Welsh JS; Berta C; Borzillary S; Sam C; Shickell D; Nobile L; Greenberg M; Weiss S; Detorie N
    Technol Cancer Res Treat; 2004 Aug; 3(4):359-64. PubMed ID: 15270586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.